VINC — Vincerx Pharma Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Brief: Vincerx Says First Patient Dosed In Phase 1B Study Of VIP152 In MYC-Driven Relapsed Or Refractory Aggressive Lymphomas, Advanced Solid Tumors
Brief: Vincerx Pharma Reports Q1 Loss Per Share $0.46
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 04:13 PM
Brief: Vincerx Pharma Announces FDA Clearance Of Ind For Phase 1B Study Of Vip152 In Chronic Lymphocytic Leukemia And Richter Syndrome
Brief: Vincera Pharma Announces Name Change To Vincerx
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:44 PM
NASDAQ RESUMED AT 09:36 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
LifeSci Acquisition: Jumps on cancer drug developer Vincera SPAC deal
Brief: Lifesci Acquisition Corp Says Merger Agreement With Vincera Pharma